U.S. Markets closed

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
106.29+0.30 (+0.28%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close105.99
Open105.01
Bid104.50 x 1000
Ask107.90 x 1100
Day's Range104.51 - 107.93
52 Week Range46.37 - 137.61
Volume518,554
Avg. Volume551,280
Market Cap5.633B
Beta (5Y Monthly)1.27
PE Ratio (TTM)34.14
EPS (TTM)3.11
Earnings DateFeb 18, 2021 - Feb 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.57
  • Emergent BioSolutions Sees Its Composite Rating Rise To 97
    Investor's Business Daily

    Emergent BioSolutions Sees Its Composite Rating Rise To 97

    Emergent Biosolutions saw its IBD SmartSelect Composite Rating rise to 97 Wednesday, up from 92 the day before.

  • Emergent BioSolutions Is Looking Stronger
    TheStreet.com

    Emergent BioSolutions Is Looking Stronger

    For his final "Executive Decision" segment of Monday's Mad Money program, Jim Cramer checked in Robert Kramer, President and CEO of Emergent BioSolutions , the contract manufacturer that's seen its shares plunge $40 from their August highs. EBS shares rose 1.7% Monday, however, after the company presented at the J.P. Morgan Healthcare Conference. Kramer explained that Emergent provides several different services, from devices to therapeutics to contract development to packaging for companies big and small.

  • Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
    Zacks

    Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View

    Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.